FibroGen Initiates Phase 2/3 Trial in Italy of Pamrevlumab for Severe COVID-19

FibroGen has launched a phase 2/3 trial in Italy to evaluate pulmonary fibrosis treatment pamrevlumab in severe COVID-19 patients.

The trial will include 68 hospitalized patients who will receive either pamrevlumab or standard of care.

The company also plans to initiate two phase 2 trials in the U.S. to assess pamrevlumab vs. standard of care in patients with severe COVID-19.